Revisiting CrowdStrike: The Outage Risk Faded but the Valuation Risk Returned
Customer churn from the July 2024 outage has been negligible, but at 80x earnings and 15x revenue, CrowdStrike is priced for perfection again.
Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Customer churn from the July 2024 outage has been negligible, but at 80x earnings and 15x revenue, CrowdStrike is priced for perfection again.
Net interest income defied rate-cut models, investment banking fees surged, and normalised earnings now look closer to $52-55 billion than our prior $45-48 billion estimate.
Net retention has stabilised, AI workloads are inflecting at 300% growth, FCF margins hit 25%, and the CEO transition is behind it. The four biggest bear arguments are weakening.
Merck's 40th KEYTRUDA indication and approaching MK-0616 FDA decision tell a story about the post-patent strategy that consensus models are underestimating.
Operating income has grown sixfold since 2022. The market still thinks it is buying a retailer.
Rivian just posted positive gross margins for the first time while EV sales fell 11% industry-wide. The Volkswagen JV and R2 platform launch change the survival calculus.
Post-Kenvue JNJ trades at 22x earnings with a looming Stelara patent cliff worth $4-5 billion in annual revenue. The defensive premium is priced for a company that no longer exists.
While hardware and chip stocks spent April repricing trade war exposure, Netflix had no supply chain to worry about. The real question is whether the margin transformation from 17.8% to 29.5% in three years justifies a 40x multiple.
Precision agriculture revenue has grown from $1.8B to $4.4B in four years while total revenue declined. The market is getting the tech transformation for free.
Elliott Management is pushing for a split. The sum-of-parts shows $180-200B in value versus a $150B market cap. The GE precedent makes the case.
Marathon synergies are running 20% ahead of target. Production crossed 2 million BOE/d. We're raising our target to $145.
Block's payments app is evolving into a full-service bank for 55 million underbanked Americans. The lending ramp is in its first inning.
A $200B defence backlog, fading Pratt & Whitney charges, NATO spending tailwinds, and $36-40B in planned capital returns. The normalised PE is just 22-24x.
The 2028 patent cliff is the defining event for Merck's next decade. Tulisokibart, ADCs, and subcutaneous Keytruda are the three bets management is making.
At 20x forward revenue with Amazon embedding Buy with Prime into the platform and TikTok Shop growing fast, the consensus bull case ignores mounting competitive threats.